First Time Loading...
A

Antares Pharma Inc
NASDAQ:ATRS

Watchlist Manager
Antares Pharma Inc
NASDAQ:ATRS
Watchlist
Price: 5.59 USD Market Closed
Updated: May 5, 2024

Antares Pharma Inc
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Antares Pharma Inc
Operating Income Peer Comparison

Comparables:
JNJ
BMY
PFE
MRK
LLY

Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
A
Antares Pharma Inc
NASDAQ:ATRS
Operating Income
$27.3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Operating Income
$24.3B
CAGR 3-Years
4%
CAGR 5-Years
4%
CAGR 10-Years
3%
Bristol-Myers Squibb Co
NYSE:BMY
Operating Income
$10.5B
CAGR 3-Years
14%
CAGR 5-Years
6%
CAGR 10-Years
12%
Pfizer Inc
NYSE:PFE
Operating Income
$10.6B
CAGR 3-Years
-6%
CAGR 5-Years
11%
CAGR 10-Years
-5%
Merck & Co Inc
NYSE:MRK
Operating Income
$6.6B
CAGR 3-Years
-10%
CAGR 5-Years
-11%
CAGR 10-Years
-2%
Eli Lilly and Co
NYSE:LLY
Operating Income
$11.3B
CAGR 3-Years
19%
CAGR 5-Years
15%
CAGR 10-Years
9%

See Also

What is Antares Pharma Inc's Operating Income?
Operating Income
27.3m USD

Based on the financial report for Dec 31, 2021, Antares Pharma Inc's Operating Income amounts to 27.3m USD.

What is Antares Pharma Inc's Operating Income growth rate?
Operating Income CAGR 1Y
101%

Over the last year, the Operating Income growth was 101%.